Donate
RANKINGS & ASSESSMENTS

2026 Access to Medicine Index

Now in its tenth edition, the 2026 Access to Medicine Index marks 20 years of tracking pharmaceutical industry action on global health equity. It ranks 20 of the world’s largest pharmaceutical companies on their efforts to expand access to essential healthcare products in low- and middle-income countries. Individual company Report Cards assess performance against key access-to-medicine priorities and highlight areas for improvement.

COMING SOON | 10 November 2026

The Access to Medicine Index ranks 20 of the world's largest research-based pharmaceutical companies in how they improve access to medicine, vaccines and diagnostics in low- and middle-income countries. It has been published every two years since 2008.

The 2026 publication marks the 10th edition of the Access to Medicine Index and a significant milestone in our work to drive change across the pharmaceutical industry. Over two decades, the Foundation has worked to accelerate change in the pharmaceutical industry, encouraging companies to do more to expand access to medicine. But how far has the industry come, and what more needs to change?

As we mark this milestone, our CEO, Jayasree K. Iyer, reflects on the evolution of access, the progress made and the work that lies ahead.

20 Years of the Access to Medicine Index: Progress, lessons and what comes next

In this video, Jayasree K. Iyer, CEO of the Access to Medicine Foundation, reflects on the evolution of access to medicine over the past two decades, drawing on insights from ten editions of the Access to Medicine Index.